All In Biotech

Free tool

FAERS Monitor: Ngenla

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761184 or its brand name (Ngenla, Somatrogon-Ghla). Reports on generic versions are filed under their own applications.

Reports

1,247

Serious

206

17% of reports

Hospitalization

49

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain805
  • wrong technique in device usage process49
  • injection site erythema48
  • incorrect dose administered by device47
  • drug dose omission by device43
  • injection site swelling40
  • headache38
  • device mechanical issue36
  • needle issue36
  • device delivery system issue33
  • patient-device incompatibility33
  • off label use32
  • device leakage28
  • incorrect dose administered27
  • injection site mass27

Reports by year received

View as table
YearReports
20221
2023277
2024530
2025344
202695

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
patient-device incompatibilitySignal33857.1606.826,048
device mechanical issueSignal3644.432.21,481
injection site painSignal80544.442.634,503
incorrect dose administered by deviceSignal4730.322.91,302
needle issueSignal3620.915.1662
device delivery system issueSignal3320.414.5588
wrong technique in device usage processSignal4917.713.5757
injection site massSignal2712.38.5270
device leakageSignal2810.97.6242
drug dose omission by deviceSignal439.36.9310
injection site swellingSignal408.86.5270
injection site erythemaSignal486.54.9220
incorrect dose administered272.01.413
headache381.00.70
off label use320.60.48

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.